43404 Federal Register / Vol. 82, No. 178 / Friday, September 15, 2017 / Notices 

INTERNATIONAL TRADE 

COMMISSION 

[Investigation No. 337–TA–1071] 

Certain Wireless Audio Systems and 

Components Thereof Institution of 

Investigation 

AGENCY: U.S. International Trade 

Commission 

ACTION: Notice. 

SUMMARY: Notice is hereby given that a 

complaint was filed with the U.S. 

International Trade Commission on 

August 10, 2017, under section 337 of 

the Tariff Act of 1930, as amended, on 

behalf of Broadcom Limited of San Jose, 

California and Avago Technologies 

General IP (Singapore) Pte. Ltd. of 

Singapore. An amended complaint was 

filed on August 16, 2017, and 

supplements to the amended complaint 

were filed on August 30, 2017. The 

amended complaint, as supplemented, 

alleges violations of section 337 based 

upon the importation into the United 

States, the sale for importation, and the 

sale within the United States after 

importation of certain wireless audio 

systems and components thereof by 

reason of infringement of U.S. Patent 

No. 6,684,060 (‘‘the ’060 patent’’). The 

amended complaint further alleges that 

an industry in the United States exists 

as required by the applicable Federal 

Statute. 

The complainants request that the 

Commission institute an investigation 

and, after the investigation, issue a 

limited exclusion order and cease and 

desist orders. 

ADDRESSES: The amended complaint, as 

supplemented, except for any 

confidential information contained 

therein, is available for inspection 

during official business hours (8:45 a.m. 

to 5:15 p.m.) in the Office of the 

Secretary, U.S. International Trade 

Commission, 500 E Street SW., Room 

112, Washington, DC 20436, telephone 

(202) 205–2000. Hearing impaired 

individuals are advised that information 

on this matter can be obtained by 

contacting the Commission’s TDD 

terminal on (202) 205–1810. Persons 

with mobility impairments who will 

need special assistance in gaining access 

to the Commission should contact the 

Office of the Secretary at (202) 205– 

2000. General information concerning 

the Commission may also be obtained 

by accessing its internet server at 

https://www.usitc.gov. The public 

record for this investigation may be 

viewed on the Commission’s electronic 

docket (EDIS) at https://edis.usitc.gov. 

FOR FURTHER INFORMATION CONTACT: 

Pathenia M. Proctor, The Office of 

Unfair Import Investigations, U.S. 

International Trade Commission, 

telephone (202) 205–2560. 

SUPPLEMENTARY INFORMATION:

Authority: The authority for 

institution of this investigation is 

contained in section 337 of the Tariff 

Act of 1930, as amended, 19 U.S.C. 1337 

and in section 210.10 of the 

Commission’s Rules of Practice and 

Procedure, 19 CFR 210.10 (2017). 

Scope of Investigation: Having 

considered the amended complaint, the 

U.S. International Trade Commission, 

on September 8, 2017, ordered that— 

(1) Pursuant to subsection (b) of 

section 337 of the Tariff Act of 1930, as 

amended, an investigation be instituted 

to determine whether there is a 

violation of subsection (a)(1)(B) of 

section 337 in the importation into the 

United States, the sale for importation, 

or the sale within the United States after 

importation of certain wireless audio 

systems and components thereof by 

reason of infringement of claim 20 of the 

’060 patent; and whether an industry in 

the United States exists as required by 

subsection (a)(2) of section 337; 

(2) For the purpose of the 

investigation so instituted, the following 

are hereby named as parties upon which 

this notice of investigation shall be 

served: 

(a) The complainants are: 

Broadcom Limited, 1320 Ridder Park 

Drive, San Jose, CA 95131 

Avago Technologies General IP 

(Singapore) Pte. Ltd., 1 Yinshun 

Avenue 7, Singapore, 768923 

(b) The respondents are the following 

entities alleged to be in violation of 

section 337, and are the parties upon 

which the amended complaint is to be 

served: 

DTS, Inc., 5220 Las Virgenes Road, 

Calabasas, CA 91302 

Phorus, Inc., 5220 Las Virgenes Road, 

Calabasas, CA 91302 

MartinLogan, Ltd., 2101 Delaware 

Street, Lawrence, KS 66046–3149 

Paradigm Electronics Inc., 205 Annagem 

Boulevard, Mississauga, ON L5T 2V1, 

Canada 

Anthem Electronics, Inc., 205 Annagem 

Boulevard, Mississauga, ON L5T 2V1, 

Canada 

Wren Sound Systems, LLC, 169 

Gateshead Way, Phoenixville, PA 

19460 

McIntosh Laboratory, Inc., 2 Chambers 

Street, Binghamton, NY 13903–2699 

Definitive Technology, 11433 Cronridge 

Drive, Suite K, Owings Mills, MD 

21117 

Polk Audio Inc., 1 Viper Way, Vista, CA 

92081 

(c) The Office of Unfair Import 

Investigations, U.S. International Trade 

Commission, 500 E Street SW., Suite 

401, Washington, DC 20436; and 

(3) For the investigation so instituted, 

the Chief Administrative Law Judge, 

U.S. International Trade Commission, 

shall designate the presiding 

Administrative Law Judge. 

Responses to the amended complaint 

and the notice of investigation must be 

submitted by the named respondents in 

accordance with section 210.13 of the 

Commission’s Rules of Practice and 

Procedure, 19 CFR 210.13. Pursuant to 

19 CFR 201.16(e) and 210.13(a), such 

responses will be considered by the 

Commission if received not later than 20 

days after the date of service by the 

Commission of the amended complaint 

and the notice of investigation. 

Extensions of time for submitting 

responses to the amended complaint 

and the notice of investigation will not 

be granted unless good cause therefor is 

shown. 

Failure of a respondent to file a timely 

response to each allegation in the 

amended complaint and in this notice 

may be deemed to constitute a waiver of 

the right to appear and contest the 

allegations of the amended complaint 

and this notice, and to authorize the 

administrative law judge and the 

Commission, without further notice to 

the respondent, to find the facts to be as 

alleged in the amended complaint and 

this notice and to enter an initial 

determination and a final determination 

containing such findings, and may 

result in the issuance of an exclusion 

order or a cease and desist order or both 

directed against the respondent. 

By order of the Commission. 

Issued: September 11, 2017. 

Lisa R. Barton, 

Secretary to the Commission. 

[FR Doc. 2017–19597 Filed 9–14–17; 8:45 am] 

BILLING CODE 7020–02–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–392] 

Importer of Controlled Substances 

Application: Cerilliant Corporation 

ACTION: Notice of application. 

DATES: Registered bulk manufacturers of 

the affected basic classes, and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration on 

or before October 16, 2017. Such 

persons may also file a written request 

mstockstill on DSK30JT082PROD with NOTICES

Federal Register / Vol. 82, No. 178 / Friday, September 15, 2017 / Notices 43405 

for a hearing on the application on or 

before October 16, 2017. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/DRW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. All requests for hearing must be 

sent to: Drug Enforcement 

Administration, Attn: Administrator, 

8701 Morrissette Drive, Springfield, 

Virginia 22152. All requests for hearing 

should also be sent to: (1) Drug 

Enforcement Administration, Attn: 

Hearing Clerk/LJ, 8701 Morrissette 

Drive, Springfield, Virginia 22152; and 

(2) Drug Enforcement Administration, 

Attn: DEA Federal Register 

Representative/DRW, 8701 Morrissette 

Drive, Springfield, Virginia 22152. 

SUPPLEMENTARY INFORMATION: The 

Attorney General has delegated his 

authority under the Controlled 

Substances Act to the Administrator of 

the Drug Enforcement Administration 

(DEA), 28 CFR 0.100(b). Authority to 

exercise all necessary functions with 

respect to the promulgation and 

implementation of 21 CFR part 1301, 

incident to the registration of 

manufacturers, distributors, dispensers, 

importers, and exporters of controlled 

substances (other than final orders in 

connection with suspension, denial, or 

revocation of registration) has been 

redelegated to the Assistant 

Administrator of the DEA Diversion 

Control Division (‘‘Assistant 

Administrator’’) pursuant to section 7 of 

28 CFR part 0, appendix to subpart R. 

In accordance with 21 CFR 

1301.34(a), this is notice that on July 13, 

2017, Cerilliant Corporation, 811 

Paloma Drive, Suite A, Round Rock, 

Texas 78665 applied to be registered as 

an importer of the following basic 

classes of controlled substances: 

Controlled substance Drug code Schedule 

3-Fluoro-N-methylcathinone (3–FMC) ............................................................................................................................. 1233 I 

Cathinone ........................................................................................................................................................................ 1235 I 

Methcathinone ................................................................................................................................................................. 1237 I 

4-Fluoro-N-methylcathinone (4–FMC) ............................................................................................................................. 1238 I 

Pentedrone (a-methylaminovalerophenone) ................................................................................................................... 1246 I 

Mephedrone (4-Methyl-N-methylcathinone) .................................................................................................................... 1248 I 

4-Methyl-N-ethylcathinone (4–MEC) ............................................................................................................................... 1249 I 

Naphyrone ....................................................................................................................................................................... 1258 I 

N-Ethylamphetamine ....................................................................................................................................................... 1475 I 

N,N-Dimethylamphetamine .............................................................................................................................................. 1480 I 

Fenethylline ..................................................................................................................................................................... 1503 I 

Methaqualone .................................................................................................................................................................. 2565 I 

JWH–250 (1-Pentyl-3-(2-methoxyphenylacetyl) indole) .................................................................................................. 6250 I 

SR–18 (Also known as RCS–8) (1-Cyclohexylethyl-3-(2-methoxyphenylacetyl) indole) ................................................ 7008 I 

5-Flouro-UR-144 and XLR11 [1-(5-Fluoro-pentyl)1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone ................. 7011 I 

AB–FUBINACA (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide) ..................... 7012 I 

JWH–019 (1-Hexyl-3-(1-naphthoyl)indole) ...................................................................................................................... 7019 I 

AB–PINACA (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide) ......................................... 7023 I 

THJ–2201 [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone ................................................................... 7024 I 

AB–CHMINACA (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide ................. 7031 I 

ADB–PINACA (N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide) ................................. 7035 I

APINACA and AKB48 N-(1-Adamantyl)-1-pentyl-1H-indazole-3-carboxamide .............................................................. 7048 I 

JWH–081 (1-Pentyl-3-(1-(4-methoxynaphthoyl) indole) .................................................................................................. 7081 I 

SR–19 (Also known as RCS–4) (1-Pentyl-3-[(4-methoxy)-benzoyl] indole .................................................................... 7104 I 

JWH–018 (also known as AM678) (1-Pentyl-3-(1-naphthoyl)indole) .............................................................................. 7118 I 

JWH–122 (1-Pentyl-3-(4-methyl-1-naphthoyl) indole) ..................................................................................................... 7122 I 

UR–144 (1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone ................................................................. 7144 I 

JWH–073 (1-Butyl-3-(1-naphthoyl)indole) ....................................................................................................................... 7173 I 

JWH–200 (1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole) .......................................................................................... 7200 I 

AM2201 (1-(5-Fluoropentyl)-3-(1-naphthoyl) indole) ....................................................................................................... 7201 I 

JWH–203 (1-Pentyl-3-(2-chlorophenylacetyl) indole) ...................................................................................................... 7203 I 

PB–22 (Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate) ................................................................................................. 7222 I 

5F–PB–22 (Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate) ............................................................................ 7225 I 

Alpha-ethyltryptamine ...................................................................................................................................................... 7249 I 

Ibogaine ........................................................................................................................................................................... 7260 I 

CP–47,497 (5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl-phenol) ................................................................ 7297 I 

CP–47,497 C8 Homologue (5-(1,1-Dimethyloctyl)-2-[(1R,3S)3-hydroxycyclohexyl-phenol) .......................................... 7298 I 

Lysergic acid diethylamide .............................................................................................................................................. 7315 I 

2,5-Dimethoxy-4-(n)-propylthiophenethylamine (2C–T–7) .............................................................................................. 7348 I 

Marihuana ........................................................................................................................................................................ 7360 I 

Parahexyl ......................................................................................................................................................................... 7374 I 

Mescaline ......................................................................................................................................................................... 7381 I 

2-(4-Ethylthio-2,5-dimethoxyphenyl) ethanamine (2C–T–2 ) .......................................................................................... 7385 I 

3,4,5-Trimethoxyamphetamine ........................................................................................................................................ 7390 I 

4-Bromo-2,5-dimethoxyamphetamine ............................................................................................................................. 7391 I 

4-Bromo-2,5-dimethoxyphenethylamine .......................................................................................................................... 7392 I 

4-Methyl-2,5-dimethoxyamphetamine ............................................................................................................................. 7395 I 

2,5-Dimethoxyamphetamine ............................................................................................................................................ 7396 I 

JWH–398 (1-Pentyl-3-(4-chloro-1-naphthoyl) indole) ...................................................................................................... 7398 I 

3,4-Methylenedioxyamphetamine .................................................................................................................................... 7400 I 

5-Methoxy-3,4-methylenedioxyamphetamine .................................................................................................................. 7401 I 

N-Hydroxy-3,4-methylenedioxyamphetamine .................................................................................................................. 7402 I 

3,4-Methylenedioxy-N-ethylamphetamine ....................................................................................................................... 7404 I 

3,4-Methylenedioxymethamphetamine ............................................................................................................................ 7405 I 

4-Methoxyamphetamine .................................................................................................................................................. 7411 I 

mstockstill on DSK30JT082PROD with NOTICES

43406 Federal Register / Vol. 82, No. 178 / Friday, September 15, 2017 / Notices 

Controlled substance Drug code Schedule 

5-Methoxy-N-N-dimethyltryptamine ................................................................................................................................. 7431 I 

Alpha-methyltryptamine ................................................................................................................................................... 7432 I 

Bufotenine ........................................................................................................................................................................ 7433 I 

Diethyltryptamine ............................................................................................................................................................. 7434 I 

Dimethyltryptamine .......................................................................................................................................................... 7435 I 

Psilocybin ......................................................................................................................................................................... 7437 I 

Psilocyn ........................................................................................................................................................................... 7438 I 

5-Methoxy-N,N-diisopropyltryptamine ............................................................................................................................. 7439 I 

N-Ethyl-1-phenylcyclohexylamine .................................................................................................................................... 7455 I 

1-(1-Phenylcyclohexyl)pyrrolidine .................................................................................................................................... 7458 I 

1-[1-(2-Thienyl)cyclohexyl]piperidine ............................................................................................................................... 7470 I 

N-Benzylpiperazine .......................................................................................................................................................... 7493 I 

4-Methyl-alphapyrrolidinopropiophenone (4-MePPP) ..................................................................................................... 7498 I 

2-(2,5-Dimethoxy-4-methylphenyl) ethanamine (2C–D) .................................................................................................. 7508 I 

2-(2,5-Dimethoxy-4-ethylphenyl) ethanamine (2C–E ) .................................................................................................... 7509 I 

2-(2,5-Dimethoxyphenyl) ethanamine (2C–H) ................................................................................................................. 7517 I 

2-(4-Iodo-2,5-dimethoxyphenyl) ethanamine (2C–I) ....................................................................................................... 7518 I 

2-(4-Chloro-2,5-dimethoxyphenyl) ethanamine (2C–C) .................................................................................................. 7519 I 

2-(2,5-Dimethoxy-4-nitro-phenyl) ethanamine (2C–N) .................................................................................................... 7521 I 

2-(2,5-Dimethoxy-4-(n)-propylphenyl) ethanamine (2C–P) ............................................................................................. 7524 I 

2-(4-Isopropylthio)-2,5-dimethoxyphenyl) ethanamine (2C–T–4 ) .................................................................................. 7532 I 

MDPV (3,4-Methylenedioxypyrovalerone) ....................................................................................................................... 7535 I 

2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine (25B–NBOMe) .................................................... 7536 I 

2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine (25C–NBOMe) .................................................... 7537 I 

2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl) ethanamine (25I–NBOMe) ......................................................... 7538 I 

Methylone (3,4-Methylenedioxy-N-methylcathinone) ...................................................................................................... 7540 I 

Butylone ........................................................................................................................................................................... 7541 I 

Pentylone ......................................................................................................................................................................... 7542 I 

alpha-pyrrolidinopentiophenone (a-PVP) ........................................................................................................................ 7545 I 

alpha-pyrrolidinobutiophenone (a-PBP) .......................................................................................................................... 7546 I 

AM–694 (1-(5-Fluoropentyl)-3-(2-iodobenzoyl) indole) ................................................................................................... 7694 I 

Desomorphine ................................................................................................................................................................. 9055 I 

Etorphine (except HCl) .................................................................................................................................................... 9056 I 

Codeine methylbromide ................................................................................................................................................... 9070 I 

Heroin .............................................................................................................................................................................. 9200 I 

Morphine-N-oxide ............................................................................................................................................................ 9307 I 

Normorphine .................................................................................................................................................................... 9313 I 

Pholcodine ....................................................................................................................................................................... 9314 I 

U–47700 (3,4-dichloro-N-[2-dimethylamino)cyclohexy]-N-methylbenzamide) ................................................................ 9547 I 

AH–7921 (3,4-dichloro-N-[(1-dimethylamino)cyclohexylmethyl]benzamide)) .................................................................. 9551 I 

Acetylmethadol ................................................................................................................................................................ 9601 I 

Allylprodine ...................................................................................................................................................................... 9602 I 

Alphacetylmethadol except levo-alphacetylmethadol ...................................................................................................... 9603 I 

Alphameprodine ............................................................................................................................................................... 9604 I 

Alphamethadol ................................................................................................................................................................. 9605 I 

Betacetylmethadol ........................................................................................................................................................... 9607 I 

Betameprodine ................................................................................................................................................................ 9608 I 

Betamethadol ................................................................................................................................................................... 9609 I 

Betaprodine ..................................................................................................................................................................... 9611 I 

Dextromoramide .............................................................................................................................................................. 9613 I 

Dipipanone ....................................................................................................................................................................... 9622 I 

Hydroxypethidine ............................................................................................................................................................. 9627 I 

Noracymethadol ............................................................................................................................................................... 9633 I 

Norlevorphanol ................................................................................................................................................................ 9634 I 

Normethadone ................................................................................................................................................................. 9635 I 

Racemoramide ................................................................................................................................................................ 9645 I 

Trimeperidine ................................................................................................................................................................... 9646 I 

1-Methyl-4-phenyl-4-propionoxypiperidine ...................................................................................................................... 9661 I 

Tilidine ............................................................................................................................................................................. 9750 I 

Para-Fluorofentanyl ......................................................................................................................................................... 9812 I 

3-Methylfentanyl .............................................................................................................................................................. 9813 I 

Alpha-methylfentanyl ....................................................................................................................................................... 9814 I 

Acetyl-alpha-methylfentanyl ............................................................................................................................................. 9815 I 

Beta-hydroxyfentanyl ....................................................................................................................................................... 9830 I 

Beta-hydroxy-3-methylfentanyl ........................................................................................................................................ 9831 I 

Alpha-methylthiofentanyl ................................................................................................................................................. 9832 I 

3-Methylthiofentanyl ......................................................................................................................................................... 9833 I 

Thiofentanyl ..................................................................................................................................................................... 9835 I 

Methamphetamine ........................................................................................................................................................... 1105 II 

Methylphenidate .............................................................................................................................................................. 1724 II 

Amobarbital ...................................................................................................................................................................... 2125 II 

Pentobarbital .................................................................................................................................................................... 2270 II 

Secobarbital ..................................................................................................................................................................... 2315 II 

Glutethimide ..................................................................................................................................................................... 2550 II 

mstockstill on DSK30JT082PROD with NOTICES

Federal Register / Vol. 82, No. 178 / Friday, September 15, 2017 / Notices 43407 

Controlled substance Drug code Schedule 

Nabilone ........................................................................................................................................................................... 7379 II 

1-Phenylcyclohexylamine ................................................................................................................................................ 7460 II 

Phencyclidine ................................................................................................................................................................... 7471 II 

Phenylacetone ................................................................................................................................................................. 8501 II 

1-Piperidinocyclohexanecarbonitrile ................................................................................................................................ 8603 II 

Alphaprodine .................................................................................................................................................................... 9010 II 

Dihydrocodeine ................................................................................................................................................................ 9120 II 

Ecgonine .......................................................................................................................................................................... 9180 II 

Ethylmorphine .................................................................................................................................................................. 9190 II 

Levomethorphan .............................................................................................................................................................. 9210 II 

Levorphanol ..................................................................................................................................................................... 9220 II 

Meperidine ....................................................................................................................................................................... 9230 II 

Dextropropoxyphene, bulk (non-dosage forms) .............................................................................................................. 9273 II 

Levo-alphacetylmethadol ................................................................................................................................................. 9648 II 

Noroxymorphone ............................................................................................................................................................. 9668 II 

Racemethorphan ............................................................................................................................................................. 9732 II 

Alfentanil .......................................................................................................................................................................... 9737 II 

Remifentanil ..................................................................................................................................................................... 9739 II 

Sufentanil ......................................................................................................................................................................... 9740 II 

Carfentanil ....................................................................................................................................................................... 9743 II 

Tapentadol ....................................................................................................................................................................... 9780 II 

The company plans to import small 

quantities of the listed controlled 

substances for the manufacture of 

analytical reference standards and 

distribution to their research and 

forensic customers. 

In reference to drug code 7360 the 

company plans to import a synthetic 

cannabidiol. No other activity for this 

drug code is authorized for this 

registration. 

Placement of these drug codes onto 

the company’s registration does not 

translate into automatic approval of 

subsequent permit applications to 

import controlled substances. Approval 

of permit applications will occur only 

when the registrant’s business activity is 

consistent with what is authorized 

under 21 U.S.C. 952(a)(2). Authorization 

will not extend to the import of FDA 

approval or non-approved finished 

dosage forms for commercial sale. 

Dated: August 31, 2017. 

Demetra Ashley, 

Acting Assistant Administrator. 

[FR Doc. 2017–19067 Filed 9–14–17; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

National Institute of Justice 

[OMB Number 1121–NEW] 

Agency Information Collection 

Activities: Proposed New Information 

Collection Activity; Comment Request, 

Proposed Study Entitled ‘‘Evaluation of 

the Bureau of Justice Assistance 

Sexual Assault Kit Initiative’’ 

AGENCY: National Institute of Justice, 

U.S. Department of Justice. 

ACTION: 30-Day notice. 

SUMMARY: The Department of Justice 

(DOJ), Office of Justice Programs, 

National Institute of Justice, will be 

submitting the following information 

collection request to the Office of 

Management and Budget (OMB) for 

review and approval in accordance with 

the Paperwork Reduction Act of 1995. 

DATES: Comments are encouraged and 

will be accepted for 60 days until 

November 14, 2017. 

FOR FURTHER INFORMATION CONTACT: 

Written comments and/or suggestions 

regarding the items contained in this 

notice, especially the estimated public 

burden and associated response time, 

should be directed to Christine 

Crossland, National Institute of Justice, 

Office of Research & Evaluation, 810 

Seventh Street NW., Washington, DC 

20531 (overnight 20001) or via email at 

christine.crossland@ojp.usdoj.gov. 

Written comments and/or suggestions 

can also be sent to the Office of 

Management and Budget, Office of 

Information and Regulatory Affairs, 

Attention Department of Justice Desk 

Officer, Washington, DC 20503 or sent 

to OIRA_submissions@omb.eop.gov. 

SUPPLEMENTARY INFORMATION: This 

process is conducted in accordance with 

5 CFR 1320.10. Written comments and 

suggestions from the public and affected 

agencies concerning the proposed 

collection of information are 

encouraged. Your comments should 

address one or more of the following 

four points: 

—Evaluate whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the National Institute of 

Justice, including whether the 

information will have practical utility; 

—Evaluate the accuracy of the agency’s 

estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; 

—Evaluate whether, and if so how, the 

quality, utility, and clarity of the 

information to be collected can be 

enhanced; and 

—Minimize the burden of the collection 

of information on those who are to 

respond, including through the use of 

appropriate automated, electronic, 

mechanical, or other technological 

collection techniques or other forms 

of information technology, e.g., 

permitting electronic submission of 

responses. 

Overview of This Information 

Collection 

1. Type of Information Collection: Site 

visits, which will include individual 

and group interviews. 

2. The Title of the Form/Collection: 

Evaluation of the Bureau of Justice 

Assistance Sexual Assault Kit Initiative. 

3. The agency form number, if any, 

and the applicable component of the 

Department sponsoring the collection: 

The applicable component within the 

U.S. Department of Justice is the 

National Institute of Justice in the Office 

of Justice Programs. 

4. Affected public who will be asked 

or required to respond, as well as a brief 

abstract: Sexual assault kits (SAKs) are 

invaluable tools used in investigations 

to collect evidence such as DNA and to 

document injuries from alleged victims; 

this evidence in turn is used to identify 

and prosecute offenders and to 

exonerate innocent suspects. Despite the 

importance of SAKs, backlogs of 

mstockstill on DSK30JT082PROD with NOTICES